<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05024526</url>
  </required_header>
  <id_info>
    <org_study_id>FYQ2021</org_study_id>
    <nct_id>NCT05024526</nct_id>
  </id_info>
  <brief_title>Protective Effects of Edaravone Dexborneol</brief_title>
  <official_title>Protective Effects of Edaravone Dexborneol in Patients With Acute Ischemic Stroke by Improving Ischemic Penumbra and Collateral Circulation of Hypoperfusion Areas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lili Cao</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Qianfoshan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The patients of acute ischemic stroke were divided into two groups, edaravone dexborneol&#xD;
      treatment group and edaravone treatment group. The purpose of this study was to observe the&#xD;
      changes of imaging and the improvement of NIHSS and mRS in different groups.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 80 patients with acute ischemic stroke of middle cerebral artery were randomly&#xD;
      divided into two groups, edaravone dexborneol treatment group and edaravone treatment group.&#xD;
      The mismatch area between the low perfusion area of MRI 3D-ASL and the infarct area of DWI&#xD;
      was defined as the ischemic penumbra, and the CBF perfusion pseudo color images with PLD of&#xD;
      1.5s and 2.5s were recorded. The above two CBF perfusion images were subtracted, and the&#xD;
      residual area was quantitatively analyzed to reflect the establishment of collateral&#xD;
      circulation. We aimed to observe whether there were differences in the improvement of&#xD;
      ischemic penumbra and the establishment of collateral circulation between two groups after&#xD;
      treatment. Besides, the improvment of NIHSS and mRS was also observed in different periods.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>image changes in different groups</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>NIHSS changes in different groups</measure>
    <time_frame>7days，14 days, 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mRS changes in different groups</measure>
    <time_frame>7days，14 days, 90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Acute Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>edaravone dexborneol group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>edaravone group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>edaravone dexborneol or edaravone</intervention_name>
    <description>Edaravone dexborneol or edaravone is going to be used in two different groups to compare the efficacy.</description>
    <arm_group_label>edaravone dexborneol group</arm_group_label>
    <arm_group_label>edaravone group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged from 50 to 80 years old;&#xD;
&#xD;
          2. Patients diagnosed as acute ischemic stroke according to Chinese guidelines for the&#xD;
             diagnosis and treatment of acute ischemic stroke 2018 and who met the requirements of&#xD;
             middle cerebral artery blood supply area infarction (except deep perforator disease)&#xD;
             without treatment;&#xD;
&#xD;
          3. Brain MR showed that the low perfusion area of ASL was at least 20% larger than that&#xD;
             of DWI core infarct area, and the contralateral mirror brain tissue was basically&#xD;
             normal;&#xD;
&#xD;
          4. NIHSS score was between 4 to 24;&#xD;
&#xD;
          5. Patient or their legal representatives were willing to sign the informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Serious mental abnormality, complicated with heart, lung, liver, renal insufficiency&#xD;
             or malignant tumor and other serious diseases;&#xD;
&#xD;
          2. Combined with cerebral vascular malformation or cerebral hemorrhage;&#xD;
&#xD;
          3. Pregnant or lactating women;&#xD;
&#xD;
          4. Allergic to edaravone or dexborneol;&#xD;
&#xD;
          5. There are interactions between the drugs being taken by patients and the study drug or&#xD;
             affect the clinical trial parameters.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yu-Qing Fang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shandong Provincial Qianfoshan Hospital，The First Affiliated Hospital of Shandong First Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yu-Qing Fang, MD</last_name>
    <phone>+8618866883808</phone>
    <email>perfectin2000@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shandong Provincial Qianfoshan Hospital，The First Affiliated Hospital of Shandong First Medical University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250014</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lili Cao, Ph.D</last_name>
      <email>qykyc309@163.com</email>
    </contact>
    <investigator>
      <last_name>Yu-Qing Fang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 23, 2021</study_first_submitted>
  <study_first_submitted_qc>August 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2021</study_first_posted>
  <last_update_submitted>September 3, 2021</last_update_submitted>
  <last_update_submitted_qc>September 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Qianfoshan Hospital</investigator_affiliation>
    <investigator_full_name>Lili Cao</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>edaravone dexborneol</keyword>
  <keyword>ischemic penumbra</keyword>
  <keyword>NIHSS</keyword>
  <keyword>mRS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edaravone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

